TRPC6 is being explored as a biomarker for cardiotoxicity in breast cancer (NCT05507879), while TRPV6 is currently in phase I trial for advanced ovarian cancers (NCT01578564) [5]. This evidence concerns the gene TRPC6 and breast carcinoma.